# Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally

> Moderna stock drops 10% after profit taking as cancer vaccine rally fades.
- Title: Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally
- Summary: Moderna stock drops 10% after profit taking as cancer vaccine rally fades. Moderna stock fell 10% to $214.03 amid profit taking ahead of melanoma trial data.
- Keywords: moderna, biontech, pfizer, nasdaq:mrna, nasdaq:bntx, nyse:pfe, esmo, melanoma, cancer vaccine, profit taking, mrna technology, keytruda
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/16/moderna-tumbles-10-as-profit-taking-hits-cancer-vaccine-rally-biontech-eases-pfizer-stays-put
- Author: David Moadel
- Published: 2026-10-16T14:49:23+00:00
- Read time: 1 min
- Topics: moderna, biontech, pfizer, nasdaq:mrna, nasdaq:bntx, nyse:pfe, esmo, melanoma, cancer vaccine, profit taking, mrna technology, keytruda
## Moderna stock drops
Moderna stock is down 10% to $214.03 in morning trading after a steep cancer vaccine run.
## Profit taking intensifies
Profit taking is hitting one of biotech’s hottest trades, with Moderna stock falling far harder than BioNTech.
## BioNTech and Pfizer react
BioNTech stock drops 2% to $88.59 while Pfizer stock rises 0.3% to $29.54.
## Melanoma trial data
Moderna reported intismeran autogene met primary endpoint in melanoma trial, sending shares to best single-day gain ever.
## Keytruda partnership
Merck and Moderna partner on intismeran autogene, with Phase 2b showing 49% reduction in recurrence risk.
## ESMO data coming
Full melanoma data for intismeran autogene is due at ESMO Congress later this month.
## Investor caution
Investors should keep Moderna positions moderate until ESMO data confirms melanoma results.
## Key takeaway

Moderna stock fell 10% to $214.03 amid profit taking ahead of melanoma trial data.